HIPEC Combined Gastrectomy in Patients With Advanced Gastric Cancer Received Neoadjuvant Chemotherapy

Launched by ZHIXIN CAO · Mar 20, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a treatment approach for patients with advanced gastric cancer, specifically those who have not yet had surgery. The trial focuses on patients who have received chemotherapy before surgery and aims to see if a special treatment called Hyperthermic Intraperitoneal Chemotherapy (HIPEC) after surgery can improve their chances of recovery. HIPEC is a technique that delivers heated chemotherapy directly into the abdominal cavity to target any remaining cancer cells. Researchers want to determine if this method can help prevent the cancer from coming back in the peritoneal area, which is the most common issue for these patients.

To be eligible for this trial, participants must have a confirmed diagnosis of stomach cancer that has spread to nearby areas but not to distant parts of the body. They should not have had any previous chemotherapy or surgery for their cancer. Participants will need to be in good overall health and agree to follow the study's guidelines. Since the trial is not yet recruiting, those interested in participating will need to wait for it to start. If eligible, participants can expect close monitoring throughout the study and support from the medical team to ensure their safety and well-being.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • histologically proven adenocarcinoma of stomach
• • stage cT3-4N+M0
• • no involvement of esophagus \> 3 cm
• • ECOG (Eastern Cooperative Oncology Group) : 0\~1
• • no previous chemotherapy or radiotherapy for any malignancy
• • no previous surgery for GC excluding endoscopic mucosal resection or endoscopic submucosal dissection
• • Signed the Informed Consent Form
• Exclusion Criteria:
• • Serious diseases that are difficult to control
• • Severe hepatic and renal dysfunction
• • Abnormal coagulation
• • The presence of other serious physical or mental illness or laboratory abnormalities may increase the risk of participating in the study, or interfere with the results of the study, as well as the patients who the investigator believes are not suitable for participating in the study